VP22-mediated intercellular transport for suicide gene therapy under oxic and hypoxic conditions

Gene Therapy

Volumn 12, Issue 12, 2005, Pages 974-979

  Greco, O ^a,b   Joiner, M C ^a   Doleh, A ^a   Scott, S D ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bystander effect; Fusion proteins; GCV; GFP; Glioma; HSVtk

Indexed keywords

GANCICLOVIR; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PLASMID VECTOR; PROTEIN VP22; THYMIDINE KINASE;

ARTICLE; BYSTANDER EFFECT; CELL CULTURE; CELL STRAIN; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSFECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HYPOXIA; INTRACELLULAR TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SOLID TUMOR; SUICIDE GENE THERAPY;

ANALYSIS OF VARIANCE; ANOXIA; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC ENGINEERING; GLIOMA; HUMANS; TRANSFECTION; VIRAL STRUCTURAL PROTEINS;

HUMAN HERPESVIRUS 1;

EID: 21344444358     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302482     Document Type: Article

References (29)

1. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-233.
2. Elliott G, O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Therapy 1999; 6: 149-151.
3. Wybranietz WA et al. Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines. J Gene Med 1999; 1: 265-274.
4. Dilber MS et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Therapy 1999; 6: 12-21.
5. Wybranietz WA et al. Enhanced suicide gene effect by adenoviral transduction of a VP22- cytosine deaminase (CD) fusion gene. Gene Therapy 2001; 8: 1654-1664.
6. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16: 440-443.
7. Wills KN et al. Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus. J Virol 2001; 75: 8733-8741.
8. Fyles AW et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998; 48: 149-156.
9. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53: 113-117.
10. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59: 4525-4528.
11. Greco O, Marples B, Joiner MC, Scott SD. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 2003; 197: 312-325.
12. Bouvet M et al. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res 2002; 62: 1534-1540.
13. Li CY et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000; 92: 143-147.
14. Zhang W et al. Direct gap junction communication between malignant glioma cells and astrocytes. Cancer Res 1999; 59: 1994-2003.
15. Cotrina ML et al. Connexins regulate calcium signaling by controlling ATP release. Proc Natl Acad Sci USA 1998; 95: 15735-15740.
16. Greco O, Scott SD, Marples B, Dachs GU. Cancer gene therapy: 'delivery, delivery, delivery'. Front Biosci 2002; 7: d1516-d1524.
17. Lundberg M, Johansson M. Is VP22 nuclear homing an artifact? Nat Biotechnol 2001; 19: 713-714.
18. Fang B, Xu B, Koch P, Roth JA. Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells. Gene Therapy 1998; 5: 1420-1424.
19. Cashman SM et al. Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors - implications for gene therapy. Mol Ther 2002; 6: 813-823.
20. Zavaglia D et al. Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein. Gene Therapy 2003; 10: 314-325.
21. Tupper J, Greco O, Tozer GM, Dachs GU. Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dimensional tumor model. Cancer Gene Ther 2004; 11: 508-513.
22. Griffiths L et al. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Therapy 2000; 7: 255-262.
23. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 1996; 93: 3525-3529.
24. Kokoris MS, Sabo P, Adman ET, Black ME. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Therapy 1999; 6: 1415-1426.
25. Zender L et al. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 2002; 123: 608-618.
26. Aints A et al. Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting. Gene Therapy 2001; 8: 1051-1056.
27. Leslie J, Rixon FJ, McLauchlan J. Overexpression of the herpes simplex virus type 1 tegument protein VP22 increases its incorporation into virus particles. Virology 1996; 220: 60-68.
28. Scott SD et al. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Therapy 2000; 7: 1121-1125.
29. Marples B et al. Development of synthetic promoters for radiation-mediated gene therapy. Gene Therapy 2000; 7: 511-517.